Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Ongoing Initiated Nov 6, 2015 (11 years ago)

Vitamin Supplement

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Superpotent Drug: The vitamin supplement contains an extremely high level of vitamin D3 (Cholecalciferol).

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Vitamin Supplement (Vial) D3, (cholecalciferol (vit D3)/lipoic acid/ubiquinol/ methylcobalamin/pyridoxine/methionine/inositol/choline bitartrate USP) capsules, 60, 120 or 180 count vials, Glades Drugs, 109 S. Lake Ave., Pahokee, FL 33476.

Drug: Methylcobalamin

Recalling firm
Glades Drugs Inc.
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0669-2016 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week.

Other Methylcobalamin recalls

See all

Other wrong potency / content recalls from 2015

All wrong potency / content recalls
Class III · Low risk

NORepinephrine Bitartrate

Subpotent Drug; confirmed results by FDA analysis after customer complaints of discoloration

Terminated Wrong potency / content Pharmedium Services, LLC NDC 61553-127-61 D-0778-2016
Class III · Low risk

NORepinephrine Bitartrate

Subpotent Drug; confirmed results by FDA analysis after customer complaints of discoloration

Terminated Wrong potency / content Pharmedium Services, LLC NDC 61553-134-61 D-0777-2016
Class III · Low risk

Lindane Lotion

Super-Potent Drug: Out of Specification Assay test results were reported for stability samples.

Terminated Wrong potency / content Morton Grove Pharmaceuticals, Inc. NDC 60432-833-60 D-0571-2016